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FREQUENCY AND RISK FACTORS OF GOUT FLARES IN A LARGE 
POPULATION-BASED COHORT OF INCIDENT GOUT
Rothenbacher D1, Primatesta P1, Ferreira A1, Cea Soriano L2, Garcia LA2
1Novartis Pharma AG, Basel, Switzerland; 2CEIFE—Centro Español de Investigación 
Farmacoepidemiológica, Madrid, Spain
OBJECTIVES: To describe the frequency and risk factors of gout ﬂ ares in a large 
cohort of incident gout. METHODS: A cohort study was conducted in an UK general 
practice database (The Health Improvement network (THIN)) in the study period 
January 2000 through December 2008. All patients aged 20–89 years diagnosed with 
incident gout between the years 2000–2007 were included; their history of ﬂ ares 
recorded over time. We studied the association between several factors and the number 
of ﬂ ares. a Cox proportional hazards model was used to identify determinants of risk 
of ﬁ rst ﬂ are. RESULTS: The overall incidence rate of gout was 2.68 (95% conﬁ dence 
interval (CI) 2.65–2.72) per 1,000 person-years, and 23,857 incident gout patients 
(mean age 61.9 years) were included in this study. The incidence rate of a ﬁ rst ﬂ are 
was 13.7 (95% CI 13.4–14.0) per 100 person-years. The proportion of patients with 
at least one ﬂ are during the follow-up period (mean 3.8 years) was 36.9% (n = 8,806). 
Male gender, alcohol consumption and history of cardiometabolic diseases were posi-
tively associated with number of ﬂ ares (P < 0.001). The hazard ratio estimate of ﬁ rst 
ﬂ are associated with antecedents of renal failure disorders was 1.33 (CI 95% 1.20–
1.48), 1.41 (CI 95% 1.26–1.58) for drinking more than 42 alcohol units per week, 
and 1.22 (CI 95% 1.14–1.30) for a body mass index greater than 30 kg/m2. Also, a 
higher risk of a ﬁ rst ﬂ are was associated with a history of ischemic heart disease, and 
hypertension (HR: 1.12 (95% CI 1.06–1.19) and 1.15 (95% CI 1.10-1-20), respec-
tively). CONCLUSIONS: Gout ﬂ ares are the most common clinical manifestation in 
patients suffering from gout disease. Male sex, modiﬁ able life-style factors as well as 
comorbid conditions are important independent risk factors for ﬁ rst ﬂ are.
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EARLY MORTALITY RATE OF BILATERAL HIP FRACTURES OVER 60 IN 
HUNGARY
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OBJECTIVES: The aim of the study is to analyze the early mortality rate after bilateral 
hip and femur fractures over 60 in Hungary. METHODS: In this retrospective study 
the data derive from the ﬁ nancial database of the National Health Insurance Fund of 
Hungary. For the analysis we used code S7200 of the International Classiﬁ cation of 
Diseases (ICD) tenth revision. The patients included into the study had femoral neck 
fracture and being discharged from the hospital after the primary treatment in 2000. 
The patients with polytrauma were excluded from the study. The follow up was 8 
years. The patients were categorized according to sex, age, fracture type, surgical 
methods, presence of accompanying diseases and day of hospital admission. We 
analyzed the early mortality rate within 30 days after treatment of bilateral hip and 
femur fracture. RESULTS: Altogether 347 patients were included into the study. The 
national average of mortality was 7.5%. We demonstrated the following early mortal-
ity rate according to risk factors: Sex: male: 13.2%, female: 6.5%. Age groups: 
60–69 y: 5.4%, 70–79 y: 5.9%, 80 y-: 8.9%. Type of fractures: femoral neck frac-
tures: 4.2%, pertrochanteric fractures: 15.5%, femur fractures: 5.9%. Surgical tech-
niques: arthroplasty: 3.1%, osteosynthesis: 7.8%. Accompanying diseases: yes: 8.1%, 
no: 2.6%. Day of hospital admission: weekday: 7.4%, weekend: 7.7%. CONCLU-
SIONS: The early mortality rate increased with the age of patients. In the analysis 
according to sex, type of fracture and presence of accompanying diseases we found 
higher mortality in male, in patient with pertrochanteric fracture and in patient with 
accompanying diseases. According to surgical intervention early mortality rate is 
higher in patient with osteosynthesis. Many other factors can inﬂ uence this mortality, 
which will be analyzed in our further studies. 
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BUDGET IMPACT OF NEW RHBMP-2 FORMULATION IN PATIENTS 
UNDERGOING POSTEROLATERAL SPINAL FUSION PROCEDURES FOR 
DEGENERATIVE DISC DISEASE IN RANDOMIZED CONTROLLED TRIAL 
(RCT)
McInnis MM1, Olchanski N1, Kemner JE2, Goss T1
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OBJECTIVES: A new formulation of recombinant human bone morphogenetic 
protein-2 (rhBMP-2) on a Compression Resistant Matrix (CRM) evaluated in pos-
terolateral spinal fusion (PLF) procedures for degenerative disc disease (DDD) has the 
potential to improve clinical outcomes and decrease costs. The rhBMP-2/CRM pivotal 
study demonstrated signiﬁ cant improvement in spinal fusion rates compared to pro-
cedures using iliac crest bone graft (ICBG), (Dimar 2009). This study evaluated the 
likely budget impact of rhBMP-2/CRM on U.S. payer costs compared to ICBG pro-
cedures in PLF. METHODS: A budget impact model was developed to quantify clini-
cal and economic outcomes for patients with single-level symptomatic DDD and the 
U.S. payer costs of rhBMP-2/CRM in PLF procedures. The model results compare use 
of rhBMP-2/CRM to the use of ICBG in these procedures. Both study arms use pos-
terior supplemental ﬁ xation. The 24-month clinical data was derived from 463 
patients in the rhBMP-2/CRM pivotal study trial and included independent radio-
graphic assessment of fusion success rates, re-surgery rates, and complications rates 
(infections, bleeding, cardiovascular complications, GI complications). Payer costs and 
clinical practice data were derived from published sources and from the 2007 Medi-
care Inpatient Standard Analytic File and inﬂ ated to 2010 costs using the medical care 
component of the U.S. Consumer Price Index. RESULTS: The average 2-year costs 
per patient treated with ICBG were $53,740. Comparatively, treating patients with 
rhBMP-2/CRM is estimated to reduce average costs by 12% ($6,252) per patient. 
Cost reductions were primarily driven by a reduction in subsequent surgeries. Fusion 
rates at 2 years were greater in the rhBMP-2/CRM group compared to the ICBG group 
(96% vs. 89% at p = 0.014). CONCLUSIONS: This budget impact model based on 
RCT data demonstrates that the use of rhBMP-2/CRM in treatment of DDD patients 
undergoing PLF procedures is associated with substantial cost savings to payers when 
compared with traditional ICBG procedures.
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A BUDGET IMPACT MODEL FOR THE ECONOMIC ASSESSMENT OF 
TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS 
PATIENTS IN ITALY
Iannazzo S1, Zaniolo O1, Giuliani G2
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OBJECTIVES: A Budget Impact Model (BIM) was developed to assess the impact on 
Italian National Health Service (NHS) expenditure caused by the use of tocilizumab 
(TOC) , monoclonal antibody approved by EMA in early 2009, as a ﬁ rst-line biologic 
treatment vs. traditional anti-TNFα therapies in the treatment of moderate to severe 
rheumatoid arthritis (RA) patients. METHODS: A Markov model was used to simu-
late the progression of a cohort of RA patients through three lines of biologic treat-
ments with anti-TNFα and TOC, palliative therapy and death. The horizon was 5 
years. The target population was deﬁ ned by the number of incident RA patients eli-
gible to ﬁ rst-line biologic treatment based on Italian epidemiological and market data. 
First-line TOC followed by a second- and a third-line anti-TNFα treatment was 
compared a more traditional strategy based on anti-TNFα cycling. Direct medical 
costs were considered: drug acquisition, administration and monitoring tests, accord-
ing to current prices and tariffs. To estimate the relative effectiveness of use of eco-
nomic resources, the average number of patients that can be treated with an 
hypothetical annual budget of c1,000,000 was assessed. RESULTS: Italian RA 
patients eligible to a ﬁ rst-line biologic therapy were estimated in 750 per year. First-
line TOC strategy induced a decrease of costs of c805,000 (−8.6% with respect to 
anti-TNFα cycling), and c1,348,000 (−3.1%) at year 1 and year 5 respectively. The 
average annual number of patients that can be treated with c1,000,000 was 75.7 at 
year1 and 78.5 at year5 under the anti-TNFα cycling strategy, while it was 82.9 at 
year 1 and 81.8 at year 5 with ﬁ rst-line TOC, with a 9.5% to 4.3% increase. CON-
CLUSIONS: The introduction of TOC among the biologic therapies available for 
Italian RA patients represents a valuable option as it is expected to induce a reduction 
in costs and a more efﬁ cient use of health care resources.
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THE INTRODUCTION OF A GERMAN ARTHROPLASTY REGISTER: COST 
SAVINGS FOR THE HEALTH CARE SYSTEM
Held R1, Gaiser S2
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OBJECTIVES: Worldwide the numbers of ﬁ rst use—implantations and revisions in 
the hip—and knee arthroplasty are rising. In many countries corresponding arthro-
plasty—registers have been introduced in order to increase the quality of such opera-
tions. Arthroplasty—registers in countries like Sweden have been improving the 
practical operations and both realizing signiﬁ cant cost savings at national level by 
reducing the revision burden results. In Germany a similar arthroplasty—register has 
not yet been introduced. METHODS: This study examines the trends in the German 
health care system which inﬂ uences the development of clinical numbers in the ﬁ eld 
of arthroplasty and makes forecasts to 2020 on the basis of the BQS—data. In a 
further step this study takes the experiences and the results of existing arthroplasty—
registers especially from Sweden into account and makes use of it for the situation in 
Germany. The aim is to identify possible cost savings when introducing such a register 
in Germany. RESULTS: The introduction of a German arthroplasty—register for hips 
seems to make an important contribution to the quality of medical care. In addition 
considerable cost savings on a national basis might be realized by reducing the revision 
burden, which exceed the cost of an arthroplasty—register by far. CONCLUSIONS: 
If the revision burden for hip arthroplasty could be reduced by one percentage point 
cost savings of about c14–23 million per year could be realized. a reduction of about 
50 per cent like in Sweden cost savings about c81–216 million per year could be 
expected. The results of this study might be a basis of discussion among 
policymakers.
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COST AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID 
ARTHRITIS IN SOUTH KOREA
Lee TJ1, Park BH1, Sohn HG1, Song YW2, Shin K2
1Seoul National University, Seoul, South Korea; 2Seoul National University Hospital, Seoul, 
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OBJECTIVES: This study aims to estimate health care cost and productivity loss and 
to measure the quality of life in patients with rheumatoid arthritis (RA), particularly 
